Roche Annual General Meeting 2022
All proposals of the Board of Directors approvedChristoph Franz as Chairman of the Roche Board of Directors and all other Board members standing for re-election approved;Jemilah Mahmood elected as a new member of the Board of Directors35th Consecutive dividend increase to CHF 9.30 per share Basel, 15 March 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its shareholders approved all proposals of the Board of Directors at its ordinary Annual General Meeting (AGM). Owing to the ongoing high infection rates, the AGM was held with only representatives of Roche Holding Ltd and those persons req uired by the Ar...
Source: Roche Investor Update - March 15, 2022 Category: Pharmaceuticals Source Type: news
Reminder: Invitation to Roche ’s virtual event on key neuromuscular data presented at the 2022 Muscular Dystrophy Association (MDA) scientific and clinical conference
We are pleased to invite investors and analysts to participate in our virtual event onWednesday, 16 March 2022, highlighting Roche data presented during the 2022 Muscular Dystrophy Association - MDA -Virtual Clinical and Scientific Conference, from 13th to 16th March.16:30 – 17:30 CET / 15:30 - 16:30 GMT11:30 – 12:30 am EDT / 8:30 – 9:30 am PDT The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available fordownload at15:30 CET on the day of the event.>click here AgendaWelcomeBruno Eschli, Head of Investor Relations Neuromuscular franchi...
Source: Roche Investor Update - March 9, 2022 Category: Pharmaceuticals Source Type: news
Roche to present new Evrysdi data at MDA 2022 and highlight expanding neuromuscular disease portfolio
Evrysdi ® (risdiplam) data further confirm long-term efficacy and safety data in a broad range of people with spinal muscular atrophy (SMA)Latest interim results from the RAINBOWFISH study demonstrate that the majority of babies treated with Evrysdi for at least 12 months were able to sit, stand and walk within timeframes typical of healthy babiesNew gene therapy data in boys living with Duchenne muscular dystrophy (DMD) reports encouraging results from early stage study supporting its progress into global pivotal Phase III EMBARK studyBasel, 08 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new data...
Source: Roche Investor Update - March 8, 2022 Category: Pharmaceuticals Source Type: news
Roche and three leading research institutions combine expertise on new Alzheimer ’s prevention trial
Phase III trial will evaluategantenerumab in cognitively unimpaired people with the earliest biologicalsigns ofAlzheimer ' sdiseaseRoche and research institutions have jointly leveraged their scientific expertise on Alzheimer ’s disease to design the new studyBasel, 3 March 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced a new Phase III Alzheimer ’s disease prevention trial (SKYLINE, NCT05256134) with gantenerumab, an investigational anti-amyloid antibody that is administered subcutaneously. Roche intends to enter into a collaboration agreement with Banner Alzheimer’s Institute’s Alzheimer’s Prevention ...
Source: Roche Investor Update - March 3, 2022 Category: Pharmaceuticals Source Type: news
Invitation to Roche ’s virtual event on key neuromuscular data presented at the 2022 Muscular Dystrophy Association (MDA) scientific and clinical conference
We are pleased to invite investors and analysts to participate in our virtual event onWednesday, 16 March 2022, highlighting Roche data presented during the 2022 Muscular Dystrophy Association - MDA -Virtual Clinical and Scientific Conference, from 13th to 16th March.16:30 – 17:30 CET / 15:30 - 16:30 GMT11:30 – 12:30 am EDT / 8:30 – 9:30 am PDT The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available fordownload at15:30 CET on the day of the event.>click here Access to virtual event (pre-registration required)Please pre-register for o...
Source: Roche Investor Update - February 22, 2022 Category: Pharmaceuticals Source Type: news
WHO grants prequalification of Actemra/RoActemra for patients with severe or critical COVID-19
WHO ’s prequalification adds to several mechanisms already in place to improve access to Actemra/RoActemra for people with COVID-19 in low- and middle-income countriesSince the beginning of the pandemic, more than one million patients with severe COVID-19 have been treated with Actemra/RoActemra, as recommended in global treatment guidelinesTwelfth Roche medicine or test to be prequalified Basel, 11 February 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Actemra ®/RoActemra® (tocilizumab) intravenous (IV) has been granted World Health Organization (WHO) prequalification. Prequalification is a confi...
Source: Roche Investor Update - February 11, 2022 Category: Pharmaceuticals Source Type: news
WHO grants prequalification of Actemra/RoActemra for patients with severe or critical COVID-19
Basel, 11 February 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that Actemra ®/RoActemra® (tocilizumab) intravenous (IV) has been granted World Health Organization (WHO) prequalification. Prequalification is a confirmation by WHO that Actemra/RoActemra meets the WHO standards for quality, safety and efficacy for the treatment of COVID-19 in adults who are receiving systemi c corticosteroids and require supplemental oxygen or mechanical ventilation.1 It helps procurers in low- and middle-income countries identify priority medicines to improve access to care and support better health. (Source: Roche Investor Update)
Source: Roche Investor Update - February 11, 2022 Category: Pharmaceuticals Source Type: news
New two-year data for Roche ’s Vabysmo and Susvimo reinforce potential to maintain vision with fewer treatments for people with two leading causes of vision loss
This study will evaluate the efficacy, safety, and pharmacokinetics of the port delivery system with ranibizumab in participants with diabetic macular edema compared with intravitreal ranibizumab (Pagoda) [Internet; cited January 2022]. Available from:https://clinicaltrials.gov/ct2/show/NCT04108156.[14] ClinicalTrials.gov. A multicenter, randomized study in participants with diabetic retinopathy without center-involved diabetic macular edema to evaluate the efficacy, safety, and pharmacokinetics of ranibizumab delivered via the port delivery system relative to the comparator arm (PAVILION) [Internet; cited January 2022]. A...
Source: Roche Investor Update - February 11, 2022 Category: Pharmaceuticals Source Type: news
New two-year data for Roche ’s Vabysmo and Susvimo reinforce potential to maintain vision with fewer treatments for people with two leading causes of vision loss
Basel, 11 February 2022 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that new two-year data from its phase III studies of Vabysmo ™ (faricimab) and Susvimo™ (previously called Port Delivery System with ranibizumab) will be presented at Angiogenesis, Exudation and Degeneration 2022 on 12 February. These longer-term results from the Vabysmo YOSEMITE and RHINE studies in diabetic macular edema (DME) and the Susvimo Archway st udy in neovascular or “wet” age-related macular degeneration (nAMD) further reinforce the potential to allow for longer time between treatments and fewer eye injections for people with th...
Source: Roche Investor Update - February 11, 2022 Category: Pharmaceuticals Source Type: news
Reminder: Roche ’s virtual event on key ophthalmology data presented at the Angiogenesis 2022 Meeting
We are pleased to invite investors and analysts to participate in our virtual event onMonday,14 February 2022, highlighting Roche data presented at the virtual Angiogenesis, Exudation, and Degeneration 2022 Meeting, from 11th to 12th February. 16:30 – 17:45 CET / 15:30 - 16:45 GMT10:30 – 11:45 am EST / 7:30 – 8:45 am PST The webinar will start with a presentation, followed by a Q&A session (live access to the speakers). The slides will be available for download at 15:00 CET on the day of the event.>click here AgendaOphthalmology franchise strategyNilesh Mehta, Global Franchise Head, Ophthalmology O...
Source: Roche Investor Update - February 7, 2022 Category: Pharmaceuticals Source Type: news
Reminder: Roche ’s virtual event on key ophthalmology data presented at the Angiogenesis 2022 Meeting
(Source: Roche Investor Update)
Source: Roche Investor Update - February 7, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021
Basel, 3 February 2022Group sales increase 9%1 at constant exchange rates (CER); 8% in Swiss francsPharmaceuticals Divisionsales increase 3%; continued strong demand for newly launched medicines more than offsets impact of biosimilarsDiagnostics Divisionsales grow 29%; strong momentum in base business and continued high demand for COVID-19 testsMajor approvals for medicinessince the last quarter: United States: Susvimo and Vabysmo (age-related blindness)Europe: Gavreto (specific type of advanced lung cancer); Actemra/RoActemra (severe COVID-19); Ronapreve (non-hospitalised COVID-19 patients and prophylaxis)Major appro...
Source: Roche Investor Update - February 3, 2022 Category: Pharmaceuticals Source Type: news
[Ad hoc announcement pursuant to Art. 53 LR] Roche reports good results in 2021
Roche anticipates sales of COVID-19 medicines and diagnostics to decrease by approximately CHF 2 billion to around CHF 5 billion, and sales losses to biosimilars in the current year to be roughly CHF 2.5 billion. (Source: Roche Investor Update)
Source: Roche Investor Update - February 3, 2022 Category: Pharmaceuticals Source Type: news
Changes to the Roche Board of Directors and the Corporate Executive Committee
Basel, 1 February - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that William Pao (1967), M.D., Ph.D., and Head of Roche Pharma Research and Early Development (pRED) since 2018, has decided to leave Roche for a new opportunity and return to the United States, effective 18 March 2022. Johannes (Hans) Clevers (1957), M.D., Ph.D., who joined the Board of Directors in 2019, will step down from this position and be appointed the new Head of Roche pRED effective 18 March 2022. Hans Clevers will become a member of the enlarged Corporate Executive Committee and will be based in Basel. A successor to Hans Clevers ’ board po...
Source: Roche Investor Update - February 1, 2022 Category: Pharmaceuticals Source Type: news
Changes to the Roche Board of Directors and the Corporate Executive Committee
Basel, 1 February - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that William Pao (1967), M.D., Ph.D., and Head of Roche Pharma Research and Early Development (pRED) since 2018, has decided to leave Roche for a new opportunity and return to the United States, effective 18 March 2022. Johannes (Hans) Clevers (1957), M.D., Ph.D., who joined the Board of Directors in 2019, will step down from this position and be appointed the new Head of Roche pRED effective 18 March 2022. Hans Clevers will become a member of the enlarged Corporate Executive Committee and will be based in Basel. A successor to Hans Clevers ’ board po...
Source: Roche Investor Update - February 1, 2022 Category: Pharmaceuticals Source Type: news
